Asthma Care in Resource-Poor Settings

World Allergy Organization Journal

Fernan Caballero-Fonseca¹  Arnaldo Capriles-Hulett¹  Mario Sánchez-Borges¹ 

[1] Allergy and Clinical Immunology Department, Centro Médico-Docente La Trinidad, Caracas, Venezuela

关键词: socioeconomic aspects;    leukotriene receptor antagonists;    inhaled corticosteroids;    asthma therapy;    asthma;   

Others  :  1145616
DOI  :  10.1097/WOX.0b013e318213598d

【 摘 要 】

Asthma prevalence in low-to middle-income countries is at least the same or higher than in rich countries, but with increased severity. Lack of control in these settings is due to various factors such as low accessibility to effective medications, multiple and uncoordinated weak infrastructures of medical services for the management of chronic diseases such as asthma, poor compliance with prescribed therapy, lack of asthma education, and social and cultural factors. There is an urgent requirement for the implementation of better ways to treat asthma in underserved populations, enhancing the access to preventive medications and educational approaches with modern technological methods.

【 授权许可】

   
2011 World Allergy Organization; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Pearce N, Ait-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, Robertson C: The ISAAC Phase Three Study Group. Worldwide trends in the prevalence of asthma symptoms: Phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2007, 62:758-766.
• [2]Global Initiative for Asthma (GINA) Report: Global Strategy for Asthma Management and Prevention. Updated 2008. [http://www.ginasthma.com] webcite Accessed November 24, 2010
• [3]Masoli M, Fabian D, Holt S, Beasley R, Global Initiative for Asthma (GINA) Program: The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004, 59:469-478.
• [4]Lalloo UG, McIvor RA: Management of chronic asthma in adults in diverse regions of the world. Int J Tuberc Lung Dis 2006, 10:474-483.
• [5]Neffen H, Fritscher C, Schacht FC, Levy G, Chiarella P, et al.: Asthma control in Latin America: the Asthma Insights and Reality in Latin America (AIRLA) Survey. Rev Panam Salud Pública 2005, 17:191-197.
• [6]Aït-Khaled N, Auregan G, Bencharif N, Camara LM, Dagli E, et al.: Affordability of inhaled corticosteroids as a potential barrier to treatment of asthma in some developing countries. Int J Tuberc Lung Dis 2000, 4:268-271.
• [7]Sibbald B, Anderson HR, McGuigan S: Asthma and employment in young adults. Thorax 1992, 47:19-24.
• [8]Beasley R: The Global Burden of Asthma Report, Global Initiative for Asthma (GINA). Available at: http://www.ginasthma.org/2004 webcite. Accessed November 19, 2010
• [9]Chatkin JM, Cavalet-Blanco D, Scaglia NC, Tonietto RG, Wagner MB, Fritscher CC: Compliance with maintenance treatment of asthma (ADERE study). J Bras Pneumol 2006, 32:277-283.
• [10]Watson JP, Lewis RA: Is asthma treatment affordable in developing countries? Thorax 1997, 52:605-607.
• [11]Edwards PE: Asthma management at the source. Case Manager 2004, 15:59-61.
• [12]Rona RJ: Asthma and poverty. Thorax 2000, 55:239-244.
• [13]Baker D, Middleton E, Campbell S: The impact of chronic disease management in primary care on inequality in asthma severity. J Public Health Med 2003, 25:258-260.
• [14]Capriles E, Do Campo A, Verde O, Pluchino S, Capriles Hulett A: Children's asthma and the Third World: an approach. J Investig Allergol Clin Immunol 2006, 16:11-18.
• [15]Robertson CF, Price D, Henry R, Mellis C, Glasgow N, et al.: Short-course montelukast for intermittent asthma in children. A randomized controlled trial. Am J Respir Crit Care Med 2007, 175:323-329.
• [16]Johnston NW, Mandhane PJ, Dai J, Duncan JM, Greene JM, Lambert K, Sears MR: Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics 2007, 120:e702-e712.
• [17]Bisgaard H, Zielen S, Garcia-Garcia ML, Johnston SL, Gilles L, et al.: Montelukast reduces asthma exacerbations in 2-to 5-year old children with intermittent asthma. Am J Respir Crit Care Med 2005, 171:315-323.
• [18]Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Piñeiro A, et al.: Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999, 130:487-495.
• [19]Israel E, Chervinsky PS, Friedman B, Van Bavel J, Skalky CS, et al.: Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol 2002, 110:847-854.
• [20]Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R, et al.: Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007, 175:783-790.
• [21]Rabinovitch N, Strand M, Stuhlman K, Gelfand EW: Exposure to tobacco smoke increases leukotriene E4-related albuterol usage and response to montelukast. J Allergy Clin Immunol 2008, 121:1365-1371.
• [22]Griffiths C, Kaur G, Gantley M, Feder G, Hillier S, Goddard J, Packe G: Influences on hospital admission for asthma in south Asian and white adults: qualitative interview study. BMJ 2001, 323:962-966.
• [23]Moudgil H, Honeybourne D: Differences in asthma management between white European and Indian subcontinent ethnic groups living in socioeconomically deprived areas in the Birmingham (UK) conurbation. Thorax 1998, 53:490-494.
• [24]Hunninghake GM, Weiss ST, Celedón JC: Asthma in Hispanics. Am J Respir Crit Care Med 2006, 173:143-163.
• [25]Cooper PJ, Rodrigues LC, Cruz AA, Barreto ML: Asthma in Latin America: a public heath challenge and research opportunity. Allergy 2009, 64:5-17.
• [26]Rodrigo GJ, Plaza V, Bellido-Casado J, Neffen H, Bazus MT, Levy G, Armengol J: The study of severe asthma in Latin America and Spain (1994-2004): characteristics of patients hospitalized with acute severe asthma. J Bras Pneumol 2009, 35:635-644.
• [27]Neffen H, Baena-Cagnani C, Passalacqua G, Canonica GW, Rocco D: Asthma mortality, inhaled steroids and changing asthma therapy in Argentina (1990-1999). Respir Med 2006, 100:1431-1435.
• [28]Capriles-Hulett A, Carvallo C, Sánchez A, et al.: Revisión sobre el estado del asma infantil en Venezuela y una propuesta para su manejo. Rev Ven Alergia Asma Inmunol 2004, 6:25-35.
• [29]Provea. Derecho a la Salud. Informe Anual de Provea, Octubre 2006 Septiembre 2007 [http://venescopio.org.ve] webcite153-173.
• [30]Sembajwe G, Cifuentes M, Tak SW, Kriebel D, Gore R, Punnett L: National income, self-reported wheezing and asthma diagnosis from the World Health Survey. Eur Respir J 2010, 35:279-286.
• [31]Lasmar L, Fontes MJ, Mohallen MT, Fonseca AC, Camargos P: Wheezy Child Program: The experience of the Belo Horizonte Pediatric Asthma Management Program. J World Allergy Org 2009, 2:289-295.
• [32]Souza-Machado C, Souza-Machado A, Franco R, Ponte EV, Barreto ML, et al.: Rapid reduction in hospitalizations after an intervention to manage severe asthma. Eur Respir J 2010, 35:515-521.
• [33]de Oliveira MA, Faresin SM, Bruno VF, de Bittencourt AR, Fernandes AL: Evaluation of an educational programme for socially deprived asthma patients. Eur Respir J 1999, 14:908-914.